The First Targeted Therapy for KRAS-Mutated Ovarian Cancer: A 44% Response Rate, Now Available in the U.S.
- Medebound HEALTH
- Jun 24
- 7 min read
Introduction
For years, women diagnosed with low-grade serous ovarian cancer (LGSOC) with a KRAS mutation faced a hard reality: limited treatment options, repeated chemotherapy cycles, and responses that rarely lasted long. That reality changed in May 2025, when the U.S. Food and Drug Administration (FDA) granted accelerated approval to the first-ever targeted therapy specifically designed for this patient population.
The combination of avutometinib and defactinib — sold under the brand name Avmapki Fakzynja Co-pack — delivered a 44% overall response rate in the pivotal RAMP-201 clinical trial, with responses lasting a median of 31.1 months. For patients who have already been through prior treatment lines, this is not just a statistic. It represents a new, biologically targeted pathway forward.
If you or someone you love has been diagnosed with KRAS-mutated ovarian cancer, understanding this therapy — and knowing how to access expert guidance about it — could be one of the most important steps you take.
What Is Low-Grade Serous Ovarian Cancer — and Why Does KRAS Matter?
Ovarian cancer is not a single disease. Low-grade serous ovarian cancer is a distinct subtype that tends to grow more slowly than high-grade serous ovarian cancer but is notoriously resistant to standard platinum-based chemotherapy. It is also more likely to recur after initial treatment, making long-term disease management a significant challenge.
Within LGSOC, the KRAS gene mutation plays a defining biological role. KRAS (Kirsten rat sarcoma viral proto-oncogene) is a gene involved in cell signaling and growth. When mutated, it can cause cancer cells to grow and divide in an uncontrolled way. Approximately one-third of all LGSOC cases harbor a KRAS mutation — making it one of the most common and clinically significant molecular features of this cancer type.
Until 2025, no FDA-approved therapy directly targeted KRAS-mutated LGSOC. Oncologists relied on chemotherapy or endocrine (hormone) therapy — options that, while sometimes effective, often produced limited and short-lived responses. The approval of avutometinib plus defactinib changes that equation.
Avmapki Fakzynja: How This Targeted Therapy Works
Avmapki Fakzynja Co-pack is a combination of two oral targeted agents that work together to block the signaling pathways that KRAS-mutated cancer cells rely on to survive and grow.
Avutometinib (VS-6766)
Avutometinib is a RAF/MEK inhibitor. The KRAS mutation activates a downstream signaling cascade involving proteins called RAF and MEK. By blocking these proteins simultaneously, avutometinib disrupts this cascade more completely than drugs that target only one of them. This dual mechanism reduces the likelihood that cancer cells can bypass the block — a common reason single-agent MEK inhibitors lose effectiveness over time.
Defactinib (VS-6063)
Defactinib targets a separate protein called FAK (focal adhesion kinase). Cancer cells often upregulate FAK as a survival mechanism when the RAF/MEK pathway is blocked — essentially finding an escape route. By inhibiting FAK at the same time, defactinib closes that escape route and enhances the effect of avutometinib.
Both drugs are taken orally in a structured cycle: avutometinib twice weekly and defactinib twice daily for three weeks out of every four-week cycle. This continues until disease progression or unacceptable side effects.
What the Clinical Evidence Shows: The RAMP-201 Trial
The FDA approval was based on data from RAMP-201 (NCT04625270), a Phase 2, open-label, multicenter trial that enrolled 57 adult patients with measurable KRAS-mutated recurrent LGSOC who had received at least one prior systemic therapy, including a platinum-based regimen.
Key findings from RAMP-201:
44% overall response rate (ORR) — assessed by blinded independent review committee (BICR) per RECIST 1.1 criteria
Median duration of response: 31.1 months — indicating durable, not just transient, tumor control
Disease control rate of 70% at 6 months in the KRAS-mutated population
Median progression-free survival: 22 months in the KRAS-mutated group
Treatment discontinuation due to adverse events in only 10% of patients — suggesting manageable tolerability
To put the 44% response rate in context: prior standard-of-care options for recurrent LGSOC — chemotherapy or endocrine therapy — historically produced response rates in the range of 3–15%. This is why leading gynecologic oncologists have described these results as "unprecedented" for this disease setting.
The most commonly reported treatment-related side effects included nausea, diarrhea, and elevated creatine phosphokinase levels. Most were manageable and did not require treatment discontinuation.
Who Is Eligible for This Treatment?
The FDA-approved indication is specific. To be eligible for Avmapki Fakzynja, a patient must meet all of the following criteria:
Adult (18 years or older)
Diagnosed with low-grade serous ovarian cancer (LGSOC) — not high-grade
Confirmed KRAS mutation in tumor tissue, determined by local molecular testing
Have received at least one prior systemic therapy, including a platinum-based chemotherapy regimen
The first step is molecular testing. If you have been diagnosed with ovarian cancer and have not yet had biomarker or genetic testing of your tumor, asking your oncologist about KRAS mutation testing is essential. This is not a routine step in all treatment settings globally — which is one reason why a specialist second opinion can be so valuable.
Why Seek a U.S. Cancer Second Opinion for KRAS-Mutated Ovarian Cancer?
Access to breakthrough therapies like Avmapki Fakzynja is not uniform around the world. Many countries outside the United States have not yet approved or made this drug available, and molecular profiling practices — the testing that determines whether a patient even has a KRAS mutation — vary significantly between healthcare systems.
Seeking an ovarian cancer second opinion from a U.S. specialist can help in several concrete ways:
Comprehensive molecular review: U.S. cancer centers routinely perform next-generation sequencing (NGS) and comprehensive genomic profiling. A specialist may identify a KRAS mutation or other actionable alterations that were not previously tested for.
Treatment pathway guidance: U.S. gynecologic oncologists experienced with LGSOC can advise on whether Avmapki Fakzynja is appropriate for your specific case, including how it compares to other available options.
Clinical trial access: Several ongoing studies are evaluating next-generation KRAS-targeting strategies and combination regimens. A specialist may identify trials for which you qualify, even if you are located outside the U.S.
Surgical expertise assessment: Research, including the TRUST study, has shown that specialized gynecologic oncologists achieve better ovarian cancer outcomes than general surgeons. A second opinion can evaluate the adequacy of prior surgical management.
Independent perspective: A different specialist may assess your pathology, imaging, and history differently — and that difference can matter enormously for a rare subtype like KRAS-mutated LGSOC.
For international patients, the traditional barrier has been the requirement to travel to the United States — a process that is often costly, logistically complex, and sometimes impossible due to health or circumstances. That barrier no longer has to stand in the way of accessing expert knowledge.
How to Access a U.S. Cancer Second Opinion Without Traveling
Remote second opinion consultations with U.S. cancer specialists are now a well-established model of care. Through services like Medebound HEALTH, patients anywhere in the world can connect with top-ranked U.S. oncologists — gynecologic oncologists, molecular tumor boards, and LGSOC specialists — to receive expert review of their diagnosis and treatment plan, entirely without leaving home.
The process typically involves:
This model gives you the benefit of U.S. specialist expertise without the cost and disruption of international travel. It is not a replacement for your local care team — it is a complement to it, providing a second set of highly specialized eyes on your case.
Questions to Raise With Your Oncologist — or a U.S. Second Opinion Specialist
If you or a family member has been diagnosed with ovarian cancer — particularly LGSOC — here are questions worth asking:
Has my tumor been tested for KRAS mutations? If not, can this be done?
Am I a candidate for avutometinib plus defactinib (Avmapki Fakzynja)?
What are the expected benefits and risks of this therapy in my specific situation?
Are there active clinical trials that I should consider?
How does my current treatment plan compare to what leading U.S. ovarian cancer centers would recommend?
If this therapy is not available in my country, what are the pathways to access it?
Taking the Next Step: How Medebound HEALTH Can Help
Medebound HEALTH is an independent patient access platform that facilitates remote second opinion consultations between international patients and U.S. cancer specialists. Medebound HEALTH works with patients across a wide range of oncology diagnoses, including low-grade serous ovarian cancer and KRAS-mutated cancers, connecting them with specialists at leading U.S. cancer institutions.
Medebound HEALTH does not provide clinical treatment directly and is not affiliated with or representing any specific hospital or cancer center. Its role is to serve as a bridge — facilitating access to specialized oncology knowledge that might otherwise be out of reach due to geography, logistics, or cost.
If you are living with KRAS-mutated ovarian cancer and want to understand whether Avmapki Fakzynja is right for your situation — or whether there are other options your current team may not have considered — request a remote second opinion consultation through Medebound HEALTH.
How Medebound HEALTH Connects International Patients to Top U.S. Cancer Experts
Medebound HEALTH is a U.S.-based medical coordination service that facilitates second opinions from independent U.S.-licensed physicians affiliated with leading cancer centers such as MD Anderson, Mayo Clinic, Memorial Sloan Kettering and Johns Hopkins. Since 2016, the service has supported 3000+ international patients, primarily from Asia, seeking expert input before major oncology decisions.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
A New Era in KRAS-Mutated Ovarian Cancer Treatment
The FDA approval of avutometinib plus defactinib represents a genuine milestone — not only because it produced a 44% response rate in a disease where prior therapies rarely exceeded 15%, but because it validates a new scientific approach to KRAS-driven cancers. A mutation once considered "undruggable" is now a direct therapeutic target.
For patients with KRAS-mutated recurrent LGSOC, the message is clear: the treatment landscape has changed meaningfully, and if your current care plan does not reflect these developments, it may be time to seek additional expert input.
An ovarian cancer second opinion from a U.S. specialist is no longer reserved for patients who can fly to New York or Houston. Through remote consultation models, this expertise is accessible from virtually anywhere in the world. If you have been diagnosed with KRAS-mutated ovarian cancer, you deserve to know every option available to you — including the one that just changed the standard of care.
Disclaimer
We strive to maintain the accuracy and provide regular updates for the treatment information described in this article. However, treatment outcomes may vary between individuals. The information provided here is not intended as a diagnostic or treatment recommendation and should not replace the careful evaluation and advice of your attending physician. The service is independently operated by Medebound HEALTH and is not provided, partnered, or affiliated with any hospital center as an institution.
